Recently, our study showed that combination of dasatinib and gemcitabine exerts anti-proliferative effects by decreasing the expression of ALDH1A1 in pancreatic cancer MIA PaCa-2 cells with acquired resistance to gemcitabine [17]. Here, ALDH1A1 is linked to familial pancreatic carcinoma.